Stay updated with breaking news from Acumen Diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Net cash flow from operating activities more than doubled to S$14.7 million for 1Q2022 from S$6.2 million for 1Q2021.- Reward shareholders with interim dividend of 0.4 Singapore cent per ordinary share
Q&M Dental net profit, excluding other gains or losses, increased by 25% to S$7.2 million on S$46.8 million of revenue for quarter ended 31 March 2022
- EBITDA grew 47% for 12 months ended 31 Dec 2021- Proposed listing of 49%-owned Acumen Diagnostics on NASDAQ will enhance AOXIN's shareholder value- Growth trend in revenue expected to continue as COVID-19
CATALIST-listed AOXIN Q&M records 21% growth in revenue for full year ended 31 December 2021
Acumen Diagnostics expects a listing status on Nasdaq will provide it with ready access to the United States. . Read more at straitstimes.com.